Cargando…

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease

Emerging coronaviruses (CoVs) cause severe disease in humans, but no approved therapeutics are available. The CoV nsp14 exoribonuclease (ExoN) has complicated development of antiviral nucleosides due to its proofreading activity. We recently reported that the nucleoside analogue GS-5734 (remdesivir)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Agostini, Maria L., Andres, Erica L., Sims, Amy C., Graham, Rachel L., Sheahan, Timothy P., Lu, Xiaotao, Smith, Everett Clinton, Case, James Brett, Feng, Joy Y., Jordan, Robert, Ray, Adrian S., Cihlar, Tomas, Siegel, Dustin, Mackman, Richard L., Clarke, Michael O., Baric, Ralph S., Denison, Mark R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844999/ https://www.ncbi.nlm.nih.gov/pubmed/29511076 http://dx.doi.org/10.1128/mBio.00221-18

Ejemplares similares

Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2
por: Mackman, Richard L.
Publicado: (2022)

The coronavirus proofreading exoribonuclease mediates extensive viral recombination
por: Gribble, Jennifer, et al.
Publicado: (2021)

Broad-spectrum Investigational Agent GS-5734 for the Treatment of Ebola, MERS Coronavirus and Other Pathogenic Viral Infections with High Outbreak Potential
por: Jordan, Robert, et al.
Publicado: (2017)

GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses
por: Lo, Michael K., et al.
Publicado: (2017)

Proofreading-Deficient Coronaviruses Adapt for Increased Fitness over Long-Term Passage without Reversion of Exoribonuclease-Inactivating Mutations
por: Graepel, Kevin W., et al.
Publicado: (2017)

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
por: de Wit, Emmie, et al.
Publicado: (2020)

Coronaviruses Lacking Exoribonuclease Activity Are Susceptible to Lethal Mutagenesis: Evidence for Proofreading and Potential Therapeutics
por: Smith, Everett Clinton, et al.
Publicado: (2013)

Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses
por: Amirian, E. Susan, et al.
Publicado: (2020)

Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition
por: Ye, Wei, et al.
Publicado: (2020)

Recent knowledge in favor of remdesivir (GS-5734) as a therapeutic option for the COVID-19 infections
por: Saqrane, S., et al.
Publicado: (2021)

Corrigendum: Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition
por: Ye, Wei, et al.
Publicado: (2020)

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
por: Warren, Travis K., et al.
Publicado: (2016)

Fitness Barriers Limit Reversion of a Proofreading-Deficient Coronavirus
por: Graepel, Kevin W., et al.
Publicado: (2019)

Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase
por: Brown, Ariane J., et al.
Publicado: (2019)

Evidence for the Effectiveness of Remdesivir (GS-5734), a Nucleoside-Analog Antiviral Drug in the Inhibition of I (K(M)) or I (K(DR)) and in the Stimulation of I (MEP)
por: Chang, Wei-Ting, et al.
Publicado: (2020)

Structure and dynamics of SARS-CoV-2 proofreading exoribonuclease ExoN
por: Moeller, Nicholas H., et al.
Publicado: (2021)

Structure and dynamics of SARS-CoV-2 proofreading exoribonuclease ExoN
por: Moeller, Nicholas H., et al.
Publicado: (2022)

Small-Molecule Antiviral β-d-N(4)-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance
por: Agostini, Maria L., et al.
Publicado: (2019)

Coronaviruses: An RNA proofreading machine regulates replication fidelity and diversity
por: Denison, Mark R, et al.
Publicado: (2011)

Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets
por: Cox, Robert M., et al.
Publicado: (2021)

Correction: Coronaviruses Lacking Exoribonuclease Activity Are Susceptible to Lethal Mutagenesis: Evidence for Proofreading and Potential Therapeutics
Publicado: (2014)

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
por: Sheahan, Timothy P., et al.
Publicado: (2020)

Mutations in the SARS-CoV-2 RNA dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms
por: Stevens, Laura J., et al.
Publicado: (2022)

Coupling of N7-methyltransferase and 3′-5′ exoribonuclease with SARS-CoV-2 polymerase reveals mechanisms for capping and proofreading
por: Yan, Liming, et al.
Publicado: (2021)

Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice.
por: Schäfer, Alexandra, et al.
Publicado: (2021)

Reply to Yan and Muller, “Single-Cell RNA Sequencing Supports Preferential Bioactivation of Remdesivir in the Liver”
por: Murakami, Eisuke, et al.
Publicado: (2021)

Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment
por: Yan, Victoria C., et al.
Publicado: (2020)

Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients
por: Leegwater, E., et al.
Publicado: (2022)

Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potential
por: Martinez, David R., et al.
Publicado: (2023)

Practical and Highly Efficient Synthesis of Remdesivir from GS-441524
por: Hu, Tianwen, et al.
Publicado: (2022)

Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice
por: Pruijssers, Andrea J., et al.
Publicado: (2020)

An efficient synthesis of RNA containing GS-441524: the nucleoside precursor of remdesivir
por: Moorthy, Ramkumar, et al.
Publicado: (2021)

Transplacental transfer of Remdesivir and GS‐441524: An ex vivo perfusion study
por: Louchet, Margaux, et al.
Publicado: (2023)

Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice
por: Schäfer, Alexandra, et al.
Publicado: (2022)

Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants
por: Pitts, Jared, et al.
Publicado: (2022)

Immunosuppressive arenaviral exoribonuclease
por: Meyer, Bjoern, et al.
Publicado: (2015)

Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir
por: Jockusch, Steffen, et al.
Publicado: (2020)

Handbook for proofreading
por: Anderson, Laura Killen 1938-
Publicado: (1994)

A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance
por: Grimes, Samantha L., et al.
Publicado: (2023)

Crystallographic Studies of Bacterial Exoribonucleases
por: Fiedler, Tristan J., et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_158hoqhn85qeqbg04gcjgqb21k